Comparison of unrelated cord blood and unrelated bone marrow transplants for adults with leukemia a collaborative study: The New York blood center national cord blood program and The International bone marrow transplant registry  by Laughlin, M.J.
was 90% (95%CI: 82-98) with a median chimerism of 100% (range
72-100) by day 100. The cumulative incidences of grade II-IV and
grade III-IV acute GVHD were 61% (95%CI: 14-78) and 27%
(95%CI: 14-40) at day 100, and chronic GVHD was 36% (95%CI:
20-52) at 1 year. TRM was 18% (95%CI: 8-28) at day 180, and
relapse/progressive disease was 31% (95%CI: 17-45) at 1 year.
Regression of relapsed or persistent disease has been seen in pa-
tients with myelodysplasia and intermediate and low grade lym-
phoid malignancies (n  8). The probability of overall and pro-
gression-free survival was 57% (95%CI: 40-73) and 48% (95%CI:
32-63) at 1 year. Notably, day 180 transplant related mortality
(TRM) in patients aged 45 years was 11% (95%CI: 1-21), and in
patients with extensive prior therapy was 25% (95%CI: 6-44).
However, patients with serious co-morbidities pre-transplant had a
high TRM of 45% (95%CI: 20-70) at day 180 (p  0.01). These
data suggest that this regimen is both non-myeloablative and as-
sociated with a high incidence of donor engraftment with low
toxicity. Further, this approach appears to extend access to trans-
plant to many adults who would otherwise be ineligible based on
lack of donor and/or inability to tolerate high-dose conditioning.
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CLINICAL RESULTS IN UMBILICAL CORD BLOOD RECIPIENTS WITH
HEMATOLOGICAL MALIGNANCIES USING MYELOABLATIVE REGIMENS
Takahashi, S. University of Tokyo, Japan.
Unrelated cord blood transplantation (CBT) has now become
more common, but as yet there have been only a few reports on its
outcome in adults. We studied the clinical outcomes of 68 adult
patients with hematological malignancies who received unrelated
CBT and compared with bone marrow transplantation (BMT,
n45) from unrelated donors. All recipients received transplanta-
tions after myeloablative regimens including 12 Gy of TBI be-
tween 1996 and 2003. We analyzed the hematopoietic recovery,
rates of GVHD, risks of TRM and relapse, and DFS using Cox
proportional-hazard regression models. The time from donor-
search to transplantation was signiﬁcantly shorter among CBT
recipients (median 3 months) than BMT recipients (median 11
months). The 6 possible matches between the recipient and the
donor were scored serologically for HLA-A and B and genetically
for DRB1 alleles and the results showed 39 (87 %) matched grafts
in BMT and no complete matches in CBT. Although the number
of leukocytes for CBT was 1 log lower than in BMT, 64 out of 68
(94 percent) cord blood grafts contained more than 2.0  107 cells
per kilogram. Multivariate analysis demonstrated slow neutrophil
and platelet recoveries in CBT compared with BMT. Despite the
higher HLA mismatching rate and less use of immunosuppressive
drugs such as steroids even in recipients affected with acute GVHD
higher than grade II, probability of grades III and IV acute GVHD
was signiﬁcantly lower than among BMT recipients in multivariate
analysis. There were no GVHD-related deaths among CBT recip-
ients, compared with 10 deaths out of 24 among BMT recipi-
ents. On the other hand, There was no signiﬁcant difference
between CBT and BMT recipients in chronic GVHD inci-
dence. Unrelated CBT showed better TRM, relapse and DFS
results compared with BMT. These data strongly suggest that
CBT could be safely and effectively used for adult patients with
hematological malignancies.
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COMPARISON OF UNRELATED CORD BLOOD AND BONE MARROW
TRANSPLANTS IN ADULTS WITH ACUTE LEUKEMIA
Gluckman, E. Eurocord Hospital Saint Louis, Paris, France.
Background. Unrelated cord blood is an alternative to bone
marrow cell transplantation in patients with hematopoietic dis-
eases, mainly in children. The objective of this study was to com-
pare both sources of stem cells to treat adults with acute leukemia
(AL). Patients and Methods. We compared 98 adults with AL
given an HLA-incompatible unrelated cord blood transplants
(UCBT) with 584 HLA-matched unrelated bone marrow trans-
plants (UBMT) performed between 1998 and 2002 and reported to
the Eurocord and European Blood and Marrow Transplant regis-
try. Outcomes were compared using multivariate analysis to adjust
for confounding clinical factors. Results. Recipients of UCBT
were younger (median 24.5 versus 32 years, p0.001), weighed less
(median 58 versus 68 kg, p0.001), and had more advanced disease
at transplant (52% versus 33%, p0.001). All UBMT were HLA-
matched whereas most of UCBT were HLA-incompatible
(p0.0001). The median number of nucleated cord blood cells
infused was 0.23  108/kg compared with 2.9  108/kg nucleated
bone marrow cells (p0.001). Multivariate analysis demon-
strated lower risks of grade II-IV acute graft versus-host disease
(p0.001) after UCBT, however neutrophil recovery was sig-
niﬁcantly delayed (p0.001). Transplantation-related mortality,
relapse, chronic GvHD, and leukemia-free survival were com-
parable between UCBT and UBMT recipients. Conclusion.
These results suggest that UCBT is an alternative treatment for
adults with AL lacking an HLA-matched sibling bone marrow
donor.
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UNRELATED-DONOR CORD BLOOD TRANSPLANTATION IN PATIENTS
WITH CHRONIC MYELOID LEUKEMIA
Sanz, G.F., Moscardó, F., Jiménez, C., Lorenzo, I., Planelles, D.,
Larrea, L., Cervera, J., Benlloch, L., Barragán, E., Senent, L., Cantero,
S., Montesinos, P., Remigia, M.J., Sanz, M.A. Hospital Universitario
La Fe and Centro de Transfusion de la Comunidad Valenciana, Valencia,
Spain.
Despite the promising results with imatinib, allogeneic stem cell
transplantation remains the only proven curative approach for
patients with chronic myeloid leukemia (CML). This study reports
the results of unrelated-donor cord blood transplantation (UD-
CBT) in a series of 20 patients with CML treated in a single
institution. Fourteen were in chronic phase (CP; 8 in CP1 and 6 in
CP2), 2 in accelerated phase and 4 in blast crisis. Median age was
32 years (range, 16-46). Conditioning consisted of thiotepa, busul-
fan, cyclophosphamide and antithymocyte globulin, and GVHD
prophylaxis of cyclosporine and prednisone. HLA match was 5/6 in
7 cases and 4/6 in 13. The median number of nucleated and
CD34 cells infused was 1.8  107/kg (range, 1.2-4.9) and 0.8 
105/kg (range, 0.3-2.2), respectively. Median time to PMN above
0.5  109/L and to platelets above 20  109/L was 22 days (range,
10-52) and 69 days (range, 43-188), and the cumulative incidence
of myeloid and platelet engraftment was 85% and 45%, respec-
tively. Time to myeloid engraftment showed a direct relationship
with the number of CFU-GM (P .009) and CD34 cells (P .02)
infused. Platelet engraftment was faster in patients receiving a
higher number of CFU-GM (P .05), in those transplanted in CP
(P  .04) and in those not developing acute GVHD above grade I
(P  .001). Eight patients developed acute GVHD above grade II,
and 7 of 11 patients at risk had extensive chronic GVHD. With a
median follow-up of 49 months (range, 28-82), the probability of
disease-free survival (DFS) at 3 years was 40% and was related to
age (P  .01) and phase of the disease at transplant (P  .04). The
probability of DFS at 3 years was 60% for patients younger than 31
years and 57% for those transplanted in CP. Six of 8 patients aged
30 years or younger and transplanted in CP remain alive and
disease-free. These data suggest that UD-CBT is an acceptable
alternative for younger patients with CML in CP requiring trans-
plantation and lacking a HLA-matched family or unrelated bone
marrow donor.
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COMPARISON OF UNRELATED CORD BLOOD AND UNRELATED BONE
MARROW TRANSPLANTS FOR ADULTS WITH LEUKEMIA A Collabora-
tive Study: The New York Blood Center National Cord Blood Pro-
gram And The International Bone Marrow Transplant Registry
Laughlin, M.J. Case Western Reserve University, Cleveland, Ohio.
Though little is known regarding the safety and efﬁcacy of
umbilical cord blood (UCB) transplantation in adults, these are
increasingly used in older subjects. We compared the results of
169, 1-antigen mismatched UCB, 83, 1-antigen mismatched and
367, matched bone marrow (BM) transplants in patients age 16-60
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years with acute and chronic leukemia. Majority of UCB recipients
were mismatched at 2 loci. UCB recipients were younger, weighed
less, more likely to have advanced leukemia and received a lower
dose of nucleated cells. Outcomes after matched BM, mismatched
BM and UCB transplantation were compared using Cox propor-
tional hazards regression to adjust for potentially confounding
factors. Hematopoietic recovery was slower after mismatched BM
and UCB transplants. Rates of acute graft-versus-host disease
(GVHD) were similar, but chronic GVHD was higher after UCB
transplants (RR 1.97, 95% CI 1.34-2.89, p0.001). Risks of relapse
were similar. Compared to matched BM transplants, treatment-
related mortality (RR 2.09, 95% CI 1.60-2.73, p0.0001), treat-
ment failure (RR 1.56, 95% CI 1.24-1.96, p0.002) and overall
mortality (RR 1.63, 95% CI 1.29-2.06, p0.0001) was higher after
UCB transplants. Rates of treatment-related mortality, treatment
failure and overall mortality were similar after mismatched BM and
UCB transplants. Though outcomes were better after matched
transplants, in a cohort where 69% of UCB transplants were
mismatched at 2 loci and had advanced leukemia at transplantation,
outcomes were comparable to that observed after 1-antigen mis-
matched BM transplantation. Utilization of UCB units mis-
matched at 2 loci will increase donor availability for older subjects.
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HLA MATCHING IN UNRELATED HEMATOPOIETIC CELL TRANSPLAN-
TATION
Petersdorf, E.W. Department of Medicine, University of Washington,
Fred Hutchinson Cancer Research Center.
Hematopoietic cell transplantation (HCT) from unrelated do-
nors is a curative modality for hematologic malignancies. The
success of unrelated donor HCT has closely paralleled discoveries
about the genes and function of the human leukocyte antigen
(HLA) system, the major histocompatibility complex (MHC) in
humans. Availability of robust typing methods and the continued
growth of registries of HLA-typed volunteer donors have allowed
the identiﬁcation of suitable donors for increasing numbers of
patients. The clinical results of unrelated donor HCT have greatly
improved as a consequence of more complete understanding of the
immunogenetic barriers that give rise to host-versus-graft (HVG)
and graft-versus-host (GVH) reactions. Data support a new model
for optimal HLA matching of unrelated donors in which quanti-
tative and qualitative measures of donor-recipient disparity are
considered, and where stage of disease at the time of transplanta-
tion may inﬂuence the impact of HLA disparity. New HLA match-
ing data demonstrate the importance of allele matching at HLA-A,
B, C, DRB and DQB1. Routine testing of prospective patients and
their best matched donors should include high resolution DNA
typing for HLA-A, B, C, DRB1 and DQB1. Finally, if a fully
matched donor is not available, then mismatching should be lim-
ited to one or two loci, with preference to allele rather than antigen
level mismatches.
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HLA FACTORS TO CONSIDER IN SELECTING CORD BLOOD UNITS
Baxter-Lowe, L.A. University of California, San Francisco.
For unrelated umbilical cord blood transplantation, most trans-
plant centers currently use cell dose and HLA matching as impor-
tant determinants for selecting units for transplant. Several studies
have demonstrated that HLA matching improves transplant out-
comes when typing is low resolution for HLA-A and -B and
variable levels of resolution for HLA-DRB1. Although HLA
matching improves outcomes, cord blood transplants can be suc-
cessful with only 3/6 or 4/6 HLAmatches. For the cord blood units
currently searched by the NMDP, at least one 4/6 HLA-matched
cord blood unit with at least 80  107 TNC is available for nearly
all patients. It is estimated that overall, approximately 80% of
patients will have at least one 5/6 HLA-matched donor. However,
for African Americans, only about 42% will have at least one 5/6
matched unit.
For bone marrow transplantation, it has been demonstrated that
low resolution typing of HLA-A, -B, and -DRB1 is inadequate to
identify some HLA disparities that are clinically signiﬁcant. HLA
disparity detected by performing high resolution HLA typing and
typing of additional HLA loci has been associated with adverse
outcomes. It is hypothesized that the fundamental mechanisms
underlying these bone marrow transplant observations are likely to
be applicable to cord blood transplantation. This hypothesis is
being tested by the NIH COBLT study, which has reported an
interim analysis of high resolution typing of 188 donor-recipient
pairs. For these recipients, high resolution HLA-DRB1 typing was
available during donor selection; approximately 1/3 of these pairs
had additional HLA-A and -B disparity detected by retrospective
high resolution typing. Additional HLA disparity was most fre-
quently observed in Hispanic (70%) and Asian (67%) recipients.
Eight of the 188 patients received units that were matched for only
2/6 high resolution HLA types. The clinical signiﬁcance of these
HLA disparities is under investigation. Until the relationship be-
tween HLA matching and transplant outcomes is well understood,
high resolution typing might be considered for selection of cord
blood units for transplantation. This may be particularly helpful
for patients that are at highest risk for multiple underlying HLA
disparities.
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UMBILICAL CORD BLOOD VERSUS MARROW: THE SEARCH PROCESS
Barker, J., Wagner, J.E. Blood and Marrow Transplant Program,
University of Minnesota, Minneapolis, MN.
Major efforts have been made to increase minority representation
and reduce the time of the donor search. Despite these efforts,
many patients in need of urgent transplant are not able to identify
a suitable donor in a timely fashion. Factors responsible for the
prolonged search of marrow donor programs include: 1) require-
ment for allele level matching, 2) donor availability and 3) donor
attrition. In contrast, UCB has the major advantage of rapid avail-
ability and relaxed level of HLA matching. Between 2000 and
2001, the median time to obtain an UCB graft was 13.5 days as
compared to 50 days for a volunteer BM donor at the University of
Minnesota. However, the identiﬁcation of an UCB donor is most
often limited by the availability of a unit with an adequate cell dose,
particularly for adults and older adolescents. While only 30% of
adults at the University of Minnesota were able to ﬁnd an ade-
quately dosed UCB graft in 2000-2001, the availability of double
unit UCB transplantation has virtually eliminated the obstacle of
cell dose. In 2002-2003, of 122 consecutive adult transplant refer-
rals who had a formal UCB search, using UCB unit selection
criteria of 4-6/6 HLA-A,B,DRB1 match, and combining 2 units for
patients with no single unit 3.5  107 NC/kg, a satisfactory graft
was identiﬁed for all patients. While major advances have been
made, additional obstacles have been identiﬁed impacting the UCB
search process: lack of a centralized search process and absence of
standardized procedures for qualifying cord blood banks. With
major advances in the search process for both adult and UCB
donors, the choice of stem cell source today is based on diagnosis,
degree of urgency, relative availability of adequately matched BM
versus UCB of adequate match and dose, institutional research
priority and physician preference.
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CORD BLOOD TRANSPLANTATION IN GENETIC DISORDERS
Kurtzberg, J. Duke University Medical Center, Durham, NC.
Cord blood stem and progenitor cells can rescue the bone mar-
row and immune system of pediatric and some adult patients
undergoing myeloablative chemotherapy. Cord blood cells exhibit
immunologic tolerance allowing transplantation across partially
mismatched HLA barriers increasing access to allogeneic trans-
plantation therapy for patients in need. Cord blood cells may also
be capable of transdifferentiation into non-hematopoietic tissues.
This property would make this stem cell source an ideal candidate
for future cellular therapies for tissue repair and regeneration. In
our center since 1995, banked, unrelated donor umbilical cord
blood has been used to transplant 100 infants and children with
inborn errors of metabolism. The results in these pediatric patients
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